Skip to main navigationSkip to main content
The University of Southampton

Renovos receives new investment

Published: 24 January 2020
Renovos molecules
Renovos nanoclay localising molecules

University of Southampton spinout company Renovos, has received £140,000 investment from Orthopaedic Research UK (ORUK).

The investment  is from the ORUK’s newly launched Ronald Furlong Fund, established in memory of the charity’s founder and health tech experts, HS.

Renovos is a pioneer of new nanoclay gel technology RenoviteTM, which has the potential to transform orthopaedic surgery. The gel allows a 100x lower dose of powerful regenerative therapeutic agent to be precisely delivered and localised to the sites where needed, and early trial data demonstrates that it contributes to improved bone healing. This consequently offers a step-change improvement in safety, efficacy and ease of use, as well as reduced adverse events and complications compared with current orthopaedic interventions.

The £140,000 investment will support the biotech entrepreneurs in solving a key unmet need for patients with painful and debilitating bone and joint conditions.

Professor Richard OC Oreffo, Founder and CSO of Renovos said “We are delighted to receive support from ORUK, which will aid the development of our next generation orthopaedic regenerative medicine solutions, harnessing nanoclay gels to deliver bone forming agents safely and cost effectively.

“It significantly enhances Renovos’ ability to further develop innovative technologies to support the ageing population as well as younger, active individuals.”

The investment comes after a national competition, during which start-ups were evaluated by HS. and a final decision made by the ORUK scientific and investment committees.

Dr Arash Angadji, CEO of ORUK said: “We are the first charity supporting start-ups with a focus on musculoskeletal health in the UK. The Ronald Furlong Fund initiative will play an important role in assisting entrepreneurs and innovators to quickly turn ideas into reality, with measurable benefits for the entire healthcare ecosystem.

“Effective collaboration with HS. was instrumental in identifying Renovos and their exciting technology, and I am delighted to welcome them as ORUK’s first investment.”

Dr. James Somauroo, HS. Founding Partner added: “It quickly became apparent that Renovos has the potential to fundamentally change the way extremely powerful and sometimes harmful drugs are given around bone. During the interview phase we were impressed by the immense knowledge and expertise of the team and we’re now excited to join the journey and to use our networks to help take them to the next level.”

Related Staff Member

Privacy Settings